NLRP3 and acute myeloid leukemia: AML patients with activated RAS mutation also exhibit high inflammatory responses, and an article by Hamarsheh et al. showed that AML patients with KRAS mutations, a subtype of the RAS gene, have activated inflammasome pathways, with NLRP3/caspase1/IL-1β being the major contributing axis [59].Therefore, these results reveal the heterogeneity of inflammatory responses in different clinicopathological features, and the combined assessment of them can be helpful for the diagnosis and treatment of AML.